profit from every ₹100 of sales.
₹0₹100
Rubicon Research
₹1,679.30-2.30% today
+162.1% in 1 year
1-year low ₹630.251-year high ₹1,861.15
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2025 to 2026.
0%20% a year
You pay ₹112.67 for every ₹1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Rubicon Research sold, what it kept, and what it did with the cash.
Sales went from ₹12.8 billion in 2025 to ₹17.5 billion in 2026, with ₹2.47 billion of profit last year.
SalesProfit
Rubicon Research vs. similar companies
Rubicon Research grows the fastest of these 5 and is priced in the middle for its profits.
| Company | Profit from ₹100 of sales | Sales growth a year | Price per ₹1 of profit |
|---|---|---|---|
| Rubicon Research | 112.7× · Very expensive | ||
 Eli Lilly | 62.3× · Very expensive | ||
 Johnson & Johnson | 25.7× · Fair price | ||
 AbbVie | 123.4× · Very expensive | ||
 Roche | 25.5× · Fair price |
AI analysis
An AI analyst reads Rubicon Research's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of INR | 2025 | 2026 |
|---|---|---|
| 12,843 | 17,540 | |
| 9,089 | 11,979 | |
| 2,277 | 3,550 | |
| 2,679 | 4,080 | |
| – | 2,467 | |
| – | – | |
| 70.8% | 68.3% | |
| 17.7% | 20.2% | |
| – | 14.1% |
Balance sheet
| In millions of INR | 2025 | 2026 |
|---|---|---|
| Total assets | – | 23,267 |
| Cash | – | 1,857 |
| Total debt | – | 3,110 |
| Total liabilities | – | 10,379 |
| – | 12,888 | |
| – | – | |
| – | 17.9% | |
| – | 19.1% |
Cash flow
| In millions of INR | 2025 | 2026 |
|---|---|---|
| – | 2,050 | |
| – | 2,292 | |
| – | -241 | |
| Dividends paid | – | 3 |
| – | – | |
| – | 94 |
Valuation
- 112.7×
- –
- –
- 16.5×
- 15.8×
- –
- 68.4×
- -0.1%
- 0.9%
- 0.0%
Profitability
- 68.3%
- 20.2%
- 14.1%
- –
- 17.0%
- 17.0%
- –
- –
- –
- –
Growth
- +36.6%
- –
- –
- –
- –
Financial health
- 0.3×
- 0.24
- –
- 8.6×
- 2.01
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 11%of 952
Top 22%of 884
Bottom 7%of 601
Top 15%of 886
Bottom 39%of 987
0.0%of the share price, paid each year
On $1,000 invested$0a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
0.1% of its profit
Room to growStretchedMore than it earnsNews
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
43No pass
Benjamin Graham
25No pass
Philip Fisher
55No pass
Peter Lynch
93Pass
Joel Greenblatt
14No pass
Charlie Munger
51No pass
Terry Smith
49No pass
Questions about Rubicon Research
Is Rubicon Research a good stock to buy?
A solid business, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Rubicon Research AI analysis
What does Rubicon Research do?
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. It is in Drug Manufacturers - General, based in Mumbai, India.
Does Rubicon Research pay a dividend?
Yes. At today's price the dividend is 0.0% a year, about 0% of its yearly profit. In 2026 it paid out ₹3.08 million in dividends.
Is Rubicon Research stock halal?
Yes. Rubicon Research passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Rubicon Research stock done over the past year?
Up 162.1% over the past twelve months, to ₹1,679.30. It traded between ₹630.25 and ₹1,861.15 and is 9.8% below its high.
Who are Rubicon Research's competitors?
The largest listed companies in the same industry are Eli Lilly, Johnson & Johnson, AbbVie and Roche. The peers table on this page compares their profit, growth and price with Rubicon Research's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.